Author Archives: donttradeourlivesaway

Foreign drug makers urge government to review IPR think tank

Source: Economic Times 24 Nov 2014 NEW DELHI: Foreign drug makers are urging the government to review the membership of a think tank it has set up to formulate intellectual property rights (IPR) policy in the next few months, saying … Continue reading

Posted in IP Think Tank, IPR policy, US pressure on India | Leave a comment

US industry patent lobby meeting with judges foiled

Source: Economic Times 24 Nov 2014 NEW DELHI: Public health groups successfully prevented meetings that had been scheduled between a visiting delegation of a US industry patent grouping and judges of the Delhi High Court and the Intellectual Property Appellate … Continue reading

Posted in Conflict of Interest, IP Injunctions | Leave a comment

Sovaldi-‘miracle’ hepatitis C oral drug gets official nod

Source: Dawn November 21,2014 LAHORE: The Drug Regulatory Authority of Pakistan (DRAP) has finally fixed price of the ‘blockbuster’ oral drug – Sovaldi – after its registration in Pakistan, giving a good news to hepatitis C patients. The decision was … Continue reading

Posted in access to medicines, Drug Pricing, Hepatitis - C, Sofosbuvir | Leave a comment

The dirty motivation behind Gilead’s hepatitis C agreement

Source: Aljazeera November 21,2014 It’s not about increasing medicine access but about ensuring market control. Up to 150 million people worldwide suffer from chronic hepatitis C, which attacks the liver and, if left untreated, can lead to cirrhosis and cancer. … Continue reading

Posted in access to medicines, Hepatitis - C, Indian Patent Law, Patent Opposition, Voluntary License | Leave a comment

New development in the COPD drug Indaceterol

The patented COPD drug Indaceterol is imported by Novartis and sold under an agreement by Lupin at a price of Rs. 677 for a unit of ten capsules whereas Cipla’s in October 2014 launched at risk the generic version at … Continue reading

Posted in access to medicines, Drug Pricing, Revocation | Tagged , , | Leave a comment

Trading away democracy. How CETA’s investor protection rules threaten the public good in Canada and the EU

Source: Corporate Europe Observatory November 19th,2014 The first in-depth analysis of the investment provisions of the Canadian-EU free trade agreement (CETA) has found that both the EU and Canada will be exposing themselves to greater future government policy constrain, and … Continue reading

Posted in FTAs, investor state dispute | Tagged | Leave a comment

Update on Letter to Chief Justice of India by Campaign for Affordable Trastuzumab

Subsequent to the letter to Chief Justice of India by Campaign for Affordable Trastuzumab stating concerns regarding IP Owners Association (IPOA) with India judiciary ,  we have heard from the credible sources that IPOA’s meeting with IPAB and Delhi High Court … Continue reading

Posted in Campaign for Affordable Trastuzumab, Conflict of Interest | Leave a comment